Amicus Therapeutics (FOLD) Earnings Date, Estimates & Call Transcripts → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Free fold Stock Alerts $11.71 -0.15 (-1.26%) (As of 01:29 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 8EstimatedActual EPS (Feb. 28) -$0.11 Missed By -$0.05 Consensus EPS (Feb. 28) -$0.06 Get Amicus Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for FOLD and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueFOLD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.FOLD Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyOnly a fool would buy Nvidia today… Average people are too busy throwing their money into Nvidia, Google, and every other overvalued tech firm… while missing what could be the biggest story of the decade.In this new presentation – which Porter Stansberry details why this company could be the linchpin of Amicus Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20243($0.07)($0.06)($0.06) Q2 20243($0.04)($0.01)($0.02) Q3 20243$0.01$0.03$0.02 Q4 20243$0.03$0.08$0.05 FY 202412($0.07)$0.04($0.02) Q1 20251$0.03$0.03$0.03 Q2 20251$0.06$0.06$0.06 Q3 20251$0.08$0.08$0.08 Q4 20251$0.09$0.09$0.09 FY 20254$0.26$0.26 $0.26FOLD Earnings Date and InformationAmicus Therapeutics last posted its quarterly earnings results on February 28th, 2024. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.05. The firm earned $115.08 million during the quarter, compared to analysts' expectations of $115.11 million. Amicus Therapeutics has generated ($0.51) earnings per share over the last year (($0.51) diluted earnings per share). Earnings for Amicus Therapeutics are expected to grow by 1,650.00% in the coming year, from $0.02 to $0.35 per share. Amicus Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off prior year's report dates.Read More Amicus Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/8/2024Estimated)------- 2/28/2024Q4 2023($0.06)($0.11)($0.05)($0.11)$115.11 million$115.08 million11/8/2023Q3 2023($0.08)($0.07)+$0.01($0.07)$102.30 million$103.50 million 8/8/2023Q2 2023($0.12)($0.15)($0.03)($0.15)$89.57 million$94.50 million5/10/2023Q1 2023($0.13)($0.18)($0.05)($0.18)$82.14 million$86.27 million3/1/2023Q4 2022($0.13)($0.19)($0.06)($0.19)$86.95 million$88.20 million11/7/2022Q3 2022($0.19)($0.12)+$0.07($0.12)$84.55 million$81.69 million Get the Latest News and Ratings for FOLD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/4/2022Q2 2022($0.23)($0.21)+$0.02($0.21)$85.12 million$80.73 million 5/9/2022Q1 2022($0.24)($0.30)($0.06)($0.30)$76.97 million$78.72 million 2/24/2022Q4 2021($0.14)($0.29)($0.15)($0.29)$82.57 million$82.15 million 11/8/2021Q3 2021($0.18)($0.19)($0.01)($0.19)$81.42 million$79.55 million 8/4/2021Q2 2021($0.22)($0.19)+$0.03($0.19)$71.35 million$77.41 million 5/9/2021Q1 2021($0.24)($0.25)($0.01)($0.25)$71.76 million$66.40 million Amicus Therapeutics Earnings - Frequently Asked Questions When is Amicus Therapeutics's earnings date? Amicus Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off last year's report dates. Learn more on FOLD's earnings history. Did Amicus Therapeutics beat their earnings estimates last quarter? In the previous quarter, Amicus Therapeutics (NASDAQ:FOLD) missed the analysts' consensus estimate of ($0.06) by $0.05 with a reported earnings per share (EPS) of ($0.11). Learn more on analysts' earnings estimate vs. FOLD's actual earnings. How much revenue does Amicus Therapeutics generate each year? Amicus Therapeutics (NASDAQ:FOLD) has a recorded annual revenue of $399.36 million. How much profit does Amicus Therapeutics generate each year? Amicus Therapeutics (NASDAQ:FOLD) has a recorded net income of -$151.58 million. FOLD has generated -$0.51 earnings per share over the last four quarters. What is Amicus Therapeutics's EPS forecast for next year? Amicus Therapeutics's earnings are expected to grow from $0.02 per share to $0.35 per share in the next year, which is a 1,650.00% increase. More Earnings Resources from MarketBeat Related Companies: Alkermes Earnings Date BridgeBio Pharma Earnings Date Geron Earnings Date Madrigal Pharmaceuticals Earnings Date Blueprint Medicines Earnings Date Dynavax Technologies Earnings Date Ironwood Pharmaceuticals Earnings Date Ligand Pharmaceuticals Earnings Date MannKind Earnings Date Innoviva Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Lululemon Stock Implodes Post Earnings, Guidance Muted Applied Optoelectronics earnings dumper, pain now for gain later?Is Roku worth a second look after the earnings panic selloff?Dell Technologies breaks out ahead of earnings releaseNovavax’s dispute resolution and upcoming earnings callImpinj stock surges on strong earnings and guidanceAirbnb stock bulls just went all in before earnings This page (NASDAQ:FOLD) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.